

ISO/TR 10993-22:2017-07 (E)

Biological evaluation of medical devices - Part 22: Guidance on nanomaterials

Contents		Page
Foreword		v
Introduction		vi
1	Scope	1
2	Normative references	2
3	Terms and definitions	2
4	General principles	5
4.1	General considerations	5
4.2	Biological evaluation of nanomaterials	6
4.3	Categorization of nanomaterials	6
4.4	Nanomaterial equivalence	8
5	Characterization of nanomaterials	8
5.1	General considerations	8
5.2	Characterization parameters and methods	10
5.3	Use of reference materials	14
6	Sample preparation	15
6.1	General considerations	15
6.2	Special considerations for nanostructured materials	15
6.3	Special considerations for nano-objects	15
6.4	Identity, storage and stability of stock nanomaterials	17
6.5	Description of chemical composition of stock and dosing dispersions	17
6.6	Characterization of stock dispersions	18
6.7	Characterization of dosing solutions prepared from stock dispersions	18
6.8	Dose metrics	19
6.9	Additional considerations	19
6.9.1	Endotoxin	19
6.9.2	Sterilization	20
7	Release of nano-objects from medical devices	21
7.1	General considerations	21
7.2	Degradation products	22
7.3	Release of nano-objects by wear	22
7.4	In situ processing	22
8	Toxicokinetics	22
8.1	General considerations	22
8.2	Factors influencing the toxicokinetics	23
8.2.1	Physicochemical properties	23
8.2.2	Biomolecular adsorption	24
8.2.3	Exposure route	25
8.2.4	Dose	25
8.2.5	Species and gender	25
8.2.6	Measurement techniques	26
9	Toxicological evaluation	26
9.1	General considerations	26

9.2	In vitro cytotoxicity testing	27
9.2.1	General considerations	27
9.2.2	Consideration of nanomaterial interference with the assays	28
9.2.3	Consideration of relevant dose and dose metrics	28
9.2.4	Consideration of nano-object kinetics	28
9.3	Genotoxicity, carcinogenicity and reproductive toxicity	29
9.3.1	General considerations	29
9.3.2	In vitro genotoxicity tests	30
9.3.3	In vivo genotoxicity tests	31
9.3.4	Carcinogenicity	32
9.3.5	Reproductive toxicity	32
9.4	Immunotoxicity, irritation and sensitization	33
9.4.1	General considerations	33
9.4.2	Immunotoxicity	33
9.4.3	Sensitization	34
9.4.4	Irritation	35
9.5	Haemocompatibility	36
9.5.1	General considerations	36
9.5.2	Complement system activation	37
9.5.3	Specific considerations for haemocompatibility testing	37
9.6	Systemic toxicity	37
9.7	Pyrogenicity	38
9.8	Implantation	39
10	Presentation of characterization and test results	39
11	Risk assessment	40
11.1	General considerations	40
11.2	Exposure assessment	42
11.3	Biological hazard identification	43
11.4	Risk estimation	44
11.5	Risk evaluation	44
12	Biological evaluation report	44
	Bibliography	46